FIG. 1A




Chemical Structure
G4723A
1.5-2.1
sulfonated-DGN549-C
Note: The sulfur adjacent to the G4723A antibody is derived from the site specific engineered cysteine residues on the antibody

FIG. 1B


G4723A
1.5-2.1
corresponding mono-imine



ABT-199 (Venetoclax)
EOL-1
MV4-11
KG-1
Surviving Fraction
1.5
1.0
0.5
0.0
10^{-12} 10^{-11} 10^{-10} 10^{-9} 10^{-8} 10^{-7} 10^{-6} 10^{-5}
ABT-199 (M)

FIG. 2B



IMGN632
EOL-1
MV4-11
KG-1
Surviving Fraction
1.5
1.0
0.5
0.0
10^{-14} 10^{-13} 10^{-12} 10^{-11} 10^{-10} 10^{-9} 10^{-8} 10^{-7} 10^{-6} 10^{-5}
IMGN632 (M)

FIG. 2A



ABT-199 (Venetoclax)
EOL-1
MV4-11
KG-1
Molm-13
Surviving Fraction
1.5
1.0
0.5
0.0
10^{-12} 10^{-11} 10^{-10} 10^{-9} 10^{-8} 10^{-7} 10^{-6} 10^{-5}
ABT-199 (M)

FIG. 2D



IMGN632
EOL-1
MV4-11
KG-1
Molm-13
Surviving Fraction
1.5
1.0
0.5
0.0
10^{-13} 10^{-12} 10^{-11} 10^{-10} 10^{-9} 10^{-8} 10^{-7} 10^{-6} 10^{-5}
IMGN632 (M)

FIG. 2C



EOL-1
No Combo
w/ DMSO @ 0.002%
w/ Venetoclax @ 0.625 nM
w/ Venetoclax @ 1.25 nM
w/ Venetoclax @ 2.5 nM
w/ Venetoclax @ 5 nM
w/ Venetoclax @ 10 nM
w/ Venetoclax @ 20 nM
Surviving Fraction
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10-13
10-12
10-11
IMGN632 (M)

FIG. 3A



MV4-11
Surviving Fraction
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10-13
10-12
10-11
IMGN632 (M)
No Combo
w/ DMSO @ 0.002%
w/ Venetoclax @ 0.625 nM
w/ Venetoclax @ 1.25 nM
w/ Venetoclax @ 2.5 nM
w/ Venetoclax @ 5 nM
w/ Venetoclax @ 10 nM
w/ Venetoclax @ 20 nM

FIG. 3B



KG-1
No Combo
w/ DMSO @ 0.08%
w/ Venetoclax @ 100 nM
w/ Venetoclax @ 1,000 nM
Surviving Fraction
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10-10
10-9
10-8
10-7
10-6
10-5
IMGN632 (M)

FIG. 3C



Molm-13
Surviving Fraction
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10-13
10-12
10-11
IMGN632 (M)
No Combo
w/ DMSO @ 0.002%
w/ Venetoclax @ 0.625 nM
w/ Venetoclax @ 1.25 nM
w/ Venetoclax @ 2.5 nM
w/ Venetoclax @ 5 nM
w/ Venetoclax @ 10 nM
w/ Venetoclax @ 20 nM

FIG. 3D



IMGN632
1 pM
2 pM
4 pM
8 pM
Antagonism
Additivity
Synergy
Combination Index (CI)
1.5
1.0
0.5
0.0
0.1
1
10
100
Venetoclax (nM)

FIG. 4A



Antagonism
Additivity
Synergy
Combination Index (CI)
1.5
1.0
0.5
0.0
0.0
0.2
0.4
0.6
0.8
1.0
Venetoclax + IMGN632
Fraction Affected (Fa)

FIG. 4B




FIG. 4C



IMGN632
0.5 pM
1 pM
2 pM
4 pM
Antagonism
Additivity
Synergy
Combination Index (CI)
1.5
1.0
0.5
0.0
0.1
1
10
100
Venetoclax (nM)

FIG. 4D



Antagonism
Additivity
Synergy
Combination Index (CI)
1.5
1.0
0.5
0.0
0.0
0.2
0.4
0.6
0.8
1.0
Venetoclax + IMGN632
Fraction Affected (Fa)

FIG. 4E




FIG. 4F



IMGN632
1 nM
10 nM
100 nM
1,000 nM
Antagonism
Additivity
Synergy
Combination Index (CI)
1.5
1.0
0.5
0.0
10
100
1000
10000
Venetoclax (nM)

FIG. 4G



Antagonism
Additivity
Synergy
Combination Index (CI)
1.5
1.0
0.5
0.0
0.0
0.2
0.4
0.6
0.8
1.0
Venetoclax + IMGN632
Fraction Affected (Fa)

FIG. 4H




FIG. 4I



IMGN632
0.5 pM
1 pM
2 pM
4 pM
Antagonism
Additivity
Synergy
(3.69)
Combination Index (CI)
1.5
1.0
0.5
0.0
0.1
1
10
100
Venetoclax (nM)

FIG. 4J



Combination Index (CI)
1.5
1.0
0.5
0.0
(0.033, 3.69)
Antagonism
Additivity
Synergy
0.0
0.2
0.4
0.6
0.8
1.0
Venetoclax + IMGN632
Fraction Affected (Fa)

FIG. 4K




FIG. 4L



In Vivo Efficacy of the Combination of IMGN632 (Single Dose) and Venetoclax (QDx28) in EOL-1 Subcutaneous Model
A-Vehicle
B- IMGN632, 1 µg/kg
C- IMGN632, 0.5 µg/kg
D- Venetoclax, 100 mg/kg
E- IMGN632, 1 µg/kg + Venetoclax, 100 mg/kg
F- IMGN632, 0.5 µg/kg + Venetoclax, 100 mg/kg
Median Tumor Volume (mm³)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
10
20
30
40
50
60
70
80
90
Days Post Tumor Inoculation

FIG. 5



In Vivo Efficacy of the Combination of IMGN632 (QWx3) and Venetoclax (QDx28) in KG-1 Subcutaneous Model
A-Vehicle
B- IMGN632, 3 µg/kg
C- IMGN632, 10 µg/kg
D- Venetoclax, 100 mg/kg
E- IMGN632, 3 µg/kg + Venetoclax, 100 mg/kg
F- IMGN632, 10 µg/kg + Venetoclax, 100 mg/kg
Median Tumor Volume (mm3)
1200
1000
800
600
400
200
0
0
10
20
30
40
50
Days Post Tumor Inoculation

FIG. 6

In Vivo Efficacy of the Combination of IMGN632 (QWx3) and Azacitidine (QDx5) in Molm-13 Disseminated Model




FIG. 7

In Vivo Efficacy of the Combination of IMGN632 (QWx3) and Decitabine (QDx5) in Molm-13 Disseminated Model




FIG. 8



In Vivo Efficacy of the Combination of IMGN632 (Single Dose) and Azacitidine (QDx5) and Venetoclax (QDx28) in EOL-1 Subcutaneous Model
A- Vehicle
B- IMGN632, 1 µg/kg
C- Azacitidine, 3.5 mg/kg + Venetoclax, 100 mg/kg
D- IMGN632, 1 µg/kg + Azacitidine, 3.5 mg/kg + Venetoclax, 100 mg/kg
E- Azacitidine, 3.5 mg/kg
F- IMGN632, 1 µg/kg + Azacitidine, 3.5 mg/kg
Median Tumor Volume (mm³)
1500
1200
900
600
300
0
0
20
40
60
80
Days Post Tumor Inoculation

FIG. 9

In Vivo Efficacy of the Combination of IMGN632 (QWx3) and Azacitidine (QDx5) and Venetoclax (QDx28) in Molm-13 Disseminated Model




FIG. 10A

In Vivo Efficacy of the Combination of IMGN632 (QWx3) and Azacitidine (QDx5) and Venetoclax (QDx28) in Molm-13 Disseminated Model




FIG. 10B



In Vivo Efficacy of the Combination of IMGN632 (QWx3) and Azacitidine (QDx5) and Venetoclax (QDx28) in MV4-11 Disseminated Model
A- Vehicle
B- IMGN632, 1 µg/kg
C- Azacitidine, 4.5 mg/kg + Venetoclax, 100 mg/kg
D- IMGN632, 1 µg/kg + Azacitidine, 4.5 mg/kg + Venetoclax, 100 mg/kg
E- Azacitidine, 3 mg/kg + Venetoclax, 100 mg/kg
F- IMGN632, 1 µg/kg + Azacitidine, 3 mg/kg + Venetoclax, 100 mg/kg
Percent Survival
0
20
40
60
80
100
Days Post Tumor Inoculation
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140

FIG. 11